Table 2 Hydrocortisone versus cortisone acetate replacement therapy in patients with diabetes mellitus (DM)/prediabetes.
From: Prediction of diabetes mellitus induced by steroid overtreatment in adrenal insufficiency
DM/prediabetes No 42 | |||
|---|---|---|---|
Hydrocortisone No 18 | Cortisone acetate No 24 | p | |
Mean ± SD | Mean ± SD | ||
Age (years) | 46.5 ± 13.5 | 53.5 ± 10.3 | 0.087 |
Duration of disease (years) | 17.4 ± 14.9 | 18.8 ± 12.2 | 0.757 |
BMI (Kg/m2) | 27.4 ± 5.11 | 30.1 ± 5.54 | 0.141 |
WC (cm) | 97.4 ± 11.6 | 103.5 ± 15.8 | 0.203 |
DM/prediabetes No 42 | |||
|---|---|---|---|
Hydrocortisone No 18 | Cortisone acetate No 24 | ||
Subjects (%) | Subjects (%) | ||
Male | 7 (38.8%) | 6 (25%) | 0.344 |
Female | 11 (61.1%) | 18 (75%) | |
Family history of Diabetes | 5 (27.7%) | 12 (50%) | 0.149 |
Arterial hypertension | 5 (27.7%) | 8 (33.3%) | 0.701 |
Hypertriglyceridemia | 10 (55.5%) | 18 (75%) | 0.190 |
Hypercholesterolemia | 3 (16.6%) | 6 (25%) | 0.516 |
Visceral obesity | 16 (88.8%) | 16 (66.6%) | 0.099 |
DM/prediabetes No 42 | |||
|---|---|---|---|
Hydrocortisone No 18 | Cortisone acetate No 24 | p | |
Mean ± SD | Mean ± SD | ||
Metabolic parameters | |||
Total Cholesterol (mmol/l) | 5.65 ± 1.41 | 5.64 ± 0.96 | 0.979 |
HDL Cholesterol (mmol/l) | 1.78 ± 0.57 | 1.26 ± 0.31 | 0.005 |
LDL cholesterol mmol/l) | 3.06 ± 0.97 | 3.39 ± 0.87 | 0.338 |
Triglycerides (mmol/l) | 1.43 ± 0.53 | 1.99 ± 0.51 | 0.007 |
Fasting glucose (mmol/l) | 5.61 ± 2.51 | 8.41 ± 5.63 | 0.085 |
Fasting insulin (UI/ml) | 10.7 ± 9.39 | 14.2 ± 9.05 | 0.514 |
GOT (U/L) | 21.3 ± 16.9 | 25.9 ± 6.57 | 0.398 |
GPT (U/L) | 25.6 ± 17.05 | 28.4 ± 9.99 | 0.687 |
Homa 2-IR | 2.19 ± 1.56 | 2.99 ± 2.15 | 0.384 |
HbA1c (%) | 6.87 ± 1.10 | 7.78 ± 1.76 | 0.070 |
VAI | 1.85 ± 0.94 | 3.18 ± 1.25 | 0.010 |
